Sunde, Anita L;
Alsnes, Ingvild V;
Aarsland, Dag;
Ashton, Nicholas J;
Tovar-Rios, Diego A;
De Santis, Giovanni;
Blennow, Kaj;
... Kjosavik, Svein R; + view all
(2023)
Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
, 15
(2)
, Article e12439. 10.1002/dad2.12439.
Preview |
PDF
Alz Dem Diag Ass Dis Mo - 2023 - Sunde.pdf - Published Version Download (609kB) | Preview |
Abstract
INTRODUCTION: Plasma tests have demonstrated high diagnostic accuracy for identifying Alzheimer's disease pathology. To facilitate the transition to clinical utility, we assessed whether plasma storage duration and temperature affect the biomarker concentrations. METHODS: Plasma samples from 13 participants were stored at +4°C and +18°C. Concentrations of six biomarkers were measured after 2, 4, 6, 8, 10, and 24 h by single molecule array assays. RESULTS: Phosphorylated tau 181 (p-tau181), phosphorylated tau 231 (p-tau231), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) concentrations were unchanged both when stored at +4°C and +18°C. Amyloid-β 40 (Aβ40) and amyloid-β 42 (Aβ42) concentrations were stable for 24 h at +4°C but declined when stored at +18°C for longer than 6 h. This decline did not affect the Aβ42/Aβ40 ratio. DISCUSSION: Plasma samples can be stored for 24 h at +4°C or +18°C and result in valid assay results for p-tau181, p-tau231, Aβ42/Aβ40 ratio, GFAP, and NfL. HIGHLIGHTS: Plasma samples were stored for 24 h at +4°C and +18°C, mimicking clinical practice.Concentrations for Alzheimer's disease biomarkers were measured at six time-points.p-tau181, p-tau231, NfL, and GFAP concentrations were unchanged during the experiment.Storage at +18°C affected Aβ40 and Aβ42 concentrations while storage at +4°C did not. The Aβ42/Aβ40 ratio was unaffected.These plasma tests seem suitable for use in general practice.
| Type: | Article |
|---|---|
| Title: | Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/dad2.12439 |
| Publisher version: | https://doi.org/10.1002/dad2.12439 |
| Language: | English |
| Additional information: | © 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Alzheimer disease, amyloid beta, biomarker, glial fibrillary acidic protein, neurofilament protein light, phosphorylated tau, plasma, pre‐analytics |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10175268 |
Archive Staff Only
 |
View Item |
